Sarah Rutherford, MD
Hematology & Oncology · New York, NYNPI 1245467752
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $81,564 of the $103,609 with a category attached, or 78.7%. It is spread thinly across 14 manufacturers, the largest accounting for just 21.1%. 2025 is the largest year on record at $42,093, 4.9 times the $8,665 reported in 2019. Among hematology & oncology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 106 payments — averaging $977.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Seagen Inc.$22K
- Gilead$20K
- Incyte Corporation$12K
- AbbVie$11K
- ADC Therapeutics America, Inc.$9K
- Bristol Myers Squibb$7K
- plus $22K from 8 others
Across 37 payments — averaging $22,617 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$615K
- Orphai Therapeutics Inc.$129K
- Regeneron$67K
- Janssen Research & Development, LLC$27K
What the payments were for
- Consulting fees$81,56479%
- Speaking & faculty fees$9,5339%
- Travel & lodging$9,2769%
- Food & beverage$3,2363%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Seagen Inc. | 21 | $21,814 |
| Gilead | 12 | $19,847 |
| Incyte Corporation | 17 | $12,416 |
| AbbVie | 17 | $11,037 |
| ADC Therapeutics America, Inc. | 5 | $9,492 |
| Bristol Myers Squibb | 5 | $6,945 |
| Pfizer | 6 | $6,866 |
| Genmab U.S., Inc. | 12 | $3,963 |
| Karyopharm Therapeutics Inc. | 2 | $3,513 |
| E.r. Squibb & Sons, L.L.C. | 4 | $3,306 |
| Dova Pharmaceuticals | 1 | $2,500 |
| AstraZeneca | 2 | $1,861 |
| Novo Nordisk | 1 | $24 |
| Tolmar Pharmaceuticals, Inc. | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$103,609 in reported general payments places this provider in the 90th percentile of 967 hematology & oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisone | 12 | $25 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in New York
- Michael SchusterNew York$1.6M
- Charles SawyersNew York$1.6M
- Manuel Hidalgo-MedinaNew York$1.4M
- Ross LevineNew York$968K
- Joshua SabariNew York$761K
- Gail RobozNew York$738K
- Jeffrey LaurenceNew York$640K
- John AllanNew York$580K
- Ilan ShapiraNew York$475K
- John MascarenhasNew York$456K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.